FDA Clears Biosyngen's CAR-T Therapy BRG01 for Pivotal Trial in EBV-Positive ...

Retrieved on: 2024-08-13 23:14:36

Tags for this article:

Infectious causes of cancer

Lymphoma

Orphan drugs

Post-transplant lymphoproliferative disorder

Transplantation medicine

Epstein–Barr virus

Nasopharyngeal carcinoma

Tabelecleucel

Head and neck cancer

Epstein–Barr virus infection

Epstein–Barr virus-associated lymphoproliferative diseases

Click the tags to see associated articles and topics

FDA Clears Biosyngen's CAR-T Therapy BRG01 for Pivotal Trial in EBV-Positive .... View article details on hiswai:

Excerpt

Kiromic BioPharma's NSCLC T-cell Therapy Deltacel Generates Favorable PFS Data in Interim Phase 1 Trial Results ... For the 5 patients in long-term ...

Article found on: www.cgtlive.com

View Original Article